08/02/2017 - 06:19

PharmAust subsidiary Epichem posts record revenue in January

08/02/2017 - 06:19


Upgrade your subscription to use this feature.

ASX listed PharmAust’s wholly owned subsidiary Epichem has posted a record monthly revenue result for January. Pharmaust is developing a promising anti-cancer drug known as “Monepantel” at the Perth based Epichem facility that also undertakes contract work for some of the worlds leading pharmaceutical companies 

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options